The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).
David F. McDermott
Consultant or Advisory Role - Genentech; Pfizer
Judith Manola
No relevant relationships to disclose
Michael Pins
No relevant relationships to disclose
Keith T. Flaherty
No relevant relationships to disclose
Michael B. Atkins
No relevant relationships to disclose
Janice P. Dutcher
Consultant or Advisory Role - Genentech; Pfizer
Honoraria - Bayer; Genentech; Pfizer
Daniel J. George
No relevant relationships to disclose
Kim Allyson Margolin
Consultant or Advisory Role - Genentech; GlaxoSmithKline
Research Funding - Bayer; Genentech; GlaxoSmithKline; Pfizer
Robert S. DiPaola
No relevant relationships to disclose